Drug intelligence / Profile preview

SP0173

Development stage: Phase 2
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**SP0173** is an investigational Sanofi tetanus, reduced-diphtheria, and acellular pertussis vaccine adsorbed for intramuscular administration in individuals aged 10 years and older. It contains tetanus toxoid, reduced diphtheria toxoid, and *Bordetella pertussis* antigens comprising pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3. The vaccine was evaluated in a completed US Phase I/II dose- and formulation-ranging study for safety and immunogenicity in healthy adolescents, adults, and older adults.

Other names: Investigational Tdap vaccine Formulation CTdap vaccine Formulation C

Targets

FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)TT (Tetanus toxoid)

Beyond the preview

Go deeper on SP0173.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP0173.

Explore the full profile